Roche Holding AG plans to buy Spark Therapeutics Inc for US$4.8 billion, a deal that would give the Swiss drugmaker one of the first-ever therapies to treat, and potentially cure, a disease by providing a fix for a patient’s defective genes.
Roche is to pay US$114.50 a share for Philadelphia-based Spark, a 122 percent premium to the biotechnology company’s close in New York trading on Friday.
While the price is rich, Spark shares were trading above US$90 as recently as last year.
The offer was a 19 percent premium to Spark’s 52-week intraday high, Roche said.
Along with French biopharmaceutical company Ipsen SA’s agreement yesterday to acquire Clementia Pharmaceuticals Inc for as much as US$1.3 billion, the Roche deal shows how drug companies are placing big bets on the fraught but lucrative field of rare diseases.
Gene therapies, in particular, are a promising new area of medicine with the potential to cure a wide range of often-rare diseases by replacing or repairing errors in the body’s instruction manual.
Their amazing potential has been matched by breakthrough prices, as companies have sought to charge hundreds of thousands of dollars for them — or more.
The Roche deal’s premium is an outlier, but recent pharmaceutical deals have come with rich valuations.
Acquirers paid an average 45 percent premium in takeovers of listed pharmaceutical and biotechnology companies announced over the past five years, data compiled by Bloomberg show.
Spark’s therapy Luxturna treats a gene-driven form of blindness by injecting a working version of a gene called RPE65. In people with that condition, the working genes can help restore sight.
After Luxturna was approved by US regulators in 2017, Spark said it would charge US$425,000 per eye for the treatment.
Spark was founded in 2013 at Children’s Hospital of Philadelphia. Along with Luxturna, it is developing gene therapies for the bleeding disorder hemophilia, an area where Roche is seeking to broaden its presence.
Spark already has a licensing agreement with Roche’s crosstown rival, Basel-based Novartis AG. Under an agreement struck last year, Novartis has the rights to sell Luxturna outside the US.
Intel Corp chief executive officer Lip-Bu Tan (陳立武) is expected to meet with Taiwanese suppliers next month in conjunction with the opening of the Computex Taipei trade show, supply chain sources said on Monday. The visit, the first for Tan to Taiwan since assuming his new post last month, would be aimed at enhancing Intel’s ties with suppliers in Taiwan as he attempts to help turn around the struggling US chipmaker, the sources said. Tan is to hold a banquet to celebrate Intel’s 40-year presence in Taiwan before Computex opens on May 20 and invite dozens of Taiwanese suppliers to exchange views
Application-specific integrated circuit designer Faraday Technology Corp (智原) yesterday said that although revenue this quarter would decline 30 percent from last quarter, it retained its full-year forecast of revenue growth of 100 percent. The company attributed the quarterly drop to a slowdown in customers’ production of chips using Faraday’s advanced packaging technology. The company is still confident about its revenue growth this year, given its strong “design-win” — or the projects it won to help customers design their chips, Faraday president Steve Wang (王國雍) told an online earnings conference. “The design-win this year is better than we expected. We believe we will win
Quanta Computer Inc (廣達) chairman Barry Lam (林百里) is expected to share his views about the artificial intelligence (AI) industry’s prospects during his speech at the company’s 37th anniversary ceremony, as AI servers have become a new growth engine for the equipment manufacturing service provider. Lam’s speech is much anticipated, as Quanta has risen as one of the world’s major AI server suppliers. The company reported a 30 percent year-on-year growth in consolidated revenue to NT$1.41 trillion (US$43.35 billion) last year, thanks to fast-growing demand for servers, especially those with AI capabilities. The company told investors in November last year that
Power supply and electronic components maker Delta Electronics Inc (台達電) yesterday said it plans to ship its new 1 megawatt charging systems for electric trucks and buses in the first half of next year at the earliest. The new charging piles, which deliver up to 1 megawatt of charging power, are designed for heavy-duty electric vehicles, and support a maximum current of 1,500 amperes and output of 1,250 volts, Delta said in a news release. “If everything goes smoothly, we could begin shipping those new charging systems as early as in the first half of next year,” a company official said. The new
RSS